CHV Capital

CHV Capital is a corporate venture investor based in Indianapolis with strong ties to the Indiana healthcare ecosystem and a long-standing focus on healthcare innovation across digital health, medical devices and medtech, and biotech. The fund operates with check sizes in the one to five million dollar range across seed, Series A, and Series B, which positions it as a meaningful early-stage participant rather than a growth-stage anchor. As a corporate venture vehicle in a state that hosts major life-sciences employers and academic medical centers, CHV has historically combined institutional patience with sector-specific commercial relationships that can be useful for portfolio companies looking to develop pilot programs and commercial partnerships in the Midwest healthcare market.

The investment thesis spans digital health, medtech, and biotech at relatively early stages, which is unusual for a corporate venture fund and signals a willingness to engage with companies before they have meaningful commercial traction. The fund is not explicitly AI-focused, which means founders building AI-native healthcare platforms should not expect the partnership to have the same depth of technical pattern matching as a dedicated AI-in-healthcare fund. What CHV does bring is sector knowledge in medical devices and biotech, where Indiana’s industrial healthcare base produces partners with operating familiarity in regulated medical product development. For digital health founders, the fund’s relationships with Indiana-area health systems and payers can be a useful go-to-market wedge, particularly for early commercial pilots. The check size range and stage focus suggest a fund that participates as a meaningful early check in syndicates rather than as a sole lead, with conviction backed by sector-specific operating knowledge rather than by financial-only diligence.

This profile does not include a specific list of portfolio companies. Founders should consult CHV Capital’s portfolio page and pay attention to which medical device and digital health investments have progressed to commercial milestones versus which remain in earlier development stages. The portfolio’s mix across digital health, medtech, and biotech reveals the partnership’s evolving emphasis, and founders should look at which subsectors have received the most recent capital deployments. Founders should also identify which portfolio companies have established commercial relationships with major Indiana-area health systems, since those relationships often reflect the fund’s strategic value-add.

The one to five million dollar check size range positions CHV as a participant in seed and Series A rounds with occasional Series B participation. The fund is rarely the sole lead at the earliest stages, instead joining syndicates organized by sector-specialist seed funds or by regional Midwest investors. At Series A, CHV can take a meaningful position alongside larger institutional leads, and its corporate venture status provides credibility with healthcare strategic partners that pure financial VCs cannot easily replicate. Founders should plan their cap table assuming CHV will participate in pro-rata to the extent reserves permit, while understanding that as a corporate venture investor, CHV’s follow-on participation is often subject to broader strategic considerations beyond pure financial return calculus. The fund syndicates with regional Midwest investors, with healthcare specialist funds nationally, and with corporate venture arms of larger healthcare companies.

Team member names are not enumerated in the source data for this profile. Founders should consult CHV’s website to identify the current healthcare investing team and pay particular attention to which partners have prior operating experience in medical devices, biotech, or digital health versus which come from financial or strategic backgrounds. Corporate venture decision-making typically involves both the venture team and senior leadership of the parent organization, which lengthens diligence timelines but produces stronger commercial pull-through when a deal closes. Founders should plan for a longer cycle than at a comparable financial venture fund.

The most reliable path into CHV Capital is a warm introduction from a portfolio founder, from an Indiana healthcare ecosystem executive, or from a co-investor with a prior relationship with the fund. Connections through Indiana University and the broader Indianapolis-area healthcare community carry meaningful weight given the fund’s geography. Cold inbound through the firm’s website is read and converts at rates typical of corporate venture funds, which is to say modest. Communication should articulate the strategic fit with the Indiana healthcare ecosystem in addition to the financial case, since corporate venture investors weigh strategic considerations alongside pure return profile.

Founders should approach CHV Capital when they are building a digital health, medical device, or biotech company at seed through Series B and when they value Midwest healthcare strategic relationships in addition to capital. The fund is not the right fit for late-stage growth rounds, for AI-only platforms without a sector-specific commercial wedge, or for founders who need a sole lead investor rather than a participant in a broader syndicate. It is a good fit for medical device companies with regulatory pathways, for digital health companies seeking early commercial pilots in the Midwest, and for biotech companies that benefit from Indiana’s life-sciences industrial base. Founders should weigh the strategic constraints of having a corporate venture investor on the cap table when planning future commercial relationships with potentially competing healthcare organizations.